{"id":"xw003","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, XW003 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.","oneSentence":"XW003 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:13.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07434050","phase":"PHASE3","title":"A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2026-03-09","conditions":"OSA - Obstructive Sleep Apnea, Obesity","enrollment":140},{"nctId":"NCT07387094","phase":"PHASE3","title":"A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2026-03-03","conditions":"OSA - Obstructive Sleep Apnea, Obesity","enrollment":140},{"nctId":"NCT07143227","phase":"PHASE1","title":"A Study of XW003 Injection in Chinese Adolescents With Obesity","status":"RECRUITING","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2025-08-25","conditions":"Obese Adolescents, Obesity","enrollment":48},{"nctId":"NCT05680155","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2022-12-29","conditions":"T2DM, Type 2 Diabetes Mellitus","enrollment":211},{"nctId":"NCT07073417","phase":"PHASE2","title":"A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)","status":"RECRUITING","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2025-07-28","conditions":"Obesity, Weight Management","enrollment":160},{"nctId":"NCT05680129","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-01-10","conditions":"T2DM, Type 2 Diabetes Mellitus","enrollment":623},{"nctId":"NCT06335134","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-07-14","conditions":"Healthy Volunteers","enrollment":57},{"nctId":"NCT05813795","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-04-05","conditions":"Weight Management","enrollment":664},{"nctId":"NCT05111912","phase":"PHASE2","title":"Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity","status":"COMPLETED","sponsor":"Sciwind Biosciences APAC CO Pty. Ltd.","startDate":"2021-11-30","conditions":"Obesity","enrollment":206},{"nctId":"NCT04389775","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants","status":"COMPLETED","sponsor":"Sciwind Biosciences APAC CO Pty. Ltd.","startDate":"2020-03-29","conditions":"Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GLP-1 analogue","ecnoglutide"],"phase":"phase_3","status":"active","brandName":"XW003","genericName":"XW003","companyName":"Sciwind Biosciences APAC CO Pty. Ltd.","companyId":"sciwind-biosciences-apac-co-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XW003 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}